Skip to main content
Erschienen in: International Urology and Nephrology 12/2020

01.08.2020 | Nephrology - Original Paper

Application of regional citrate anticoagulation in membrane therapeutic plasma exchange

verfasst von: Fang Yuan, Zheng Li, Xiejia Li, Hong Liu

Erschienen in: International Urology and Nephrology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Both regional citrate anticoagulation (RCA) and heparin are used as anticoagulants during membrane therapeutic plasma exchange (mTPE). However, there are few reports of comparisons of the two methods. The aim of this study was to compare different anticoagulants in mTPE and observe the effectiveness, safety, and advantages of RCA.

Methods

We retrospectively included 85 patients who underwent mTPE in the past 1 year, and divided them into three groups. Patients with no bleeding tendency were administered heparin anticoagulation; patients with bleeding tendency/with liver dysfunction/who had undergone an operation were treated with RCA, or did not receive anticoagulation. In the heparin group, low-dose heparin anticoagulation was administered; in the RCA group, 4% sodium citrate solution was administered, and 10% calcium gluconate solution was pumped from the venous circuit tube. The peripheral blood platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT), and electrolytes were detected before and after treatment in all patients.

Results

A total of 255 sessions of mTPE were performed in 85 patients (2–7 times/case) with 120 sessions of heparin anticoagulation, 93 sessions of RCA, and 42 sessions of no anticoagulation. Compared with pretreatment values, the platelet count decreased by 53.7% and the PT and APTT increased (p < 0.05) in the heparin group after treatment. There were no differences in platelet count and PT before and after treatment in the RCA group. In the RCA group, the patients did not experience hypocalcemia or hypercalcemia, and no separator clotting occurred.

Conclusion

RCA is safe, feasible, and effective in mTPE, especially for patients with bleeding tendency and frequent monitoring is needed. It is worth widely developing and applying it in clinical practice.
Literatur
1.
Zurück zum Zitat Chen X, Chen N (2013) Plasma exchange in the treatment of rapidly progressive glomerulonephritis. Contrib Nephrol 181:240–247CrossRef Chen X, Chen N (2013) Plasma exchange in the treatment of rapidly progressive glomerulonephritis. Contrib Nephrol 181:240–247CrossRef
2.
Zurück zum Zitat Nakanishi T, Suzuki N, Kuragano T, Nagasawa Y, Hasuike Y (2014) Current topics in therapeutic plasmapheresis. Clin Exp Nephrol 18(1):41–49CrossRef Nakanishi T, Suzuki N, Kuragano T, Nagasawa Y, Hasuike Y (2014) Current topics in therapeutic plasmapheresis. Clin Exp Nephrol 18(1):41–49CrossRef
3.
Zurück zum Zitat Láinez-Andrés JM, Gascón-Giménez F, Coret-Ferrer F, Casanova-Estruch B, Santonja JM (2015) Therapeutic plasma exchange: applications in neurology. Rev Neurol 60(3):120–131PubMed Láinez-Andrés JM, Gascón-Giménez F, Coret-Ferrer F, Casanova-Estruch B, Santonja JM (2015) Therapeutic plasma exchange: applications in neurology. Rev Neurol 60(3):120–131PubMed
4.
Zurück zum Zitat Kindgen-Milles D, Brandenburger T, Dimski T (2018) Regional citrate anticoagulation for continuous renal replacement therapy. Curr Opin Crit Care 24(6):450–454CrossRef Kindgen-Milles D, Brandenburger T, Dimski T (2018) Regional citrate anticoagulation for continuous renal replacement therapy. Curr Opin Crit Care 24(6):450–454CrossRef
5.
Zurück zum Zitat Janssen MJ (1996) The bleeding risk in chronic haemodialysis. Preventive strategies in high-risk patients. Neth J Med 48:198–207CrossRef Janssen MJ (1996) The bleeding risk in chronic haemodialysis. Preventive strategies in high-risk patients. Neth J Med 48:198–207CrossRef
6.
Zurück zum Zitat Lee G, Arepally GM (2012) Anticoagulation techniques in apheresis: from heparin to citrate and beyond. Clin Apher 27(3):117–125CrossRef Lee G, Arepally GM (2012) Anticoagulation techniques in apheresis: from heparin to citrate and beyond. Clin Apher 27(3):117–125CrossRef
7.
Zurück zum Zitat Maharaj S, Chang S, Seegobin K, Morales J, Aysola A, Rana F, Shaikh M (2018) Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin. Exp Hematol Oncol 7:23CrossRef Maharaj S, Chang S, Seegobin K, Morales J, Aysola A, Rana F, Shaikh M (2018) Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin. Exp Hematol Oncol 7:23CrossRef
8.
Zurück zum Zitat Mollison PL (2000) The introduction of citrate as an anticoagulant for transfusion and of glucose as a red cell preservative. Br J Haematol 108:13–18CrossRef Mollison PL (2000) The introduction of citrate as an anticoagulant for transfusion and of glucose as a red cell preservative. Br J Haematol 108:13–18CrossRef
9.
Zurück zum Zitat Oudemans-van Straaten HM, Fiaccadori E, Baldwin I (2010) Anticoagulation for renal replacement therapy: different methods to improve safety. Contrib Nephro 165:251–262CrossRef Oudemans-van Straaten HM, Fiaccadori E, Baldwin I (2010) Anticoagulation for renal replacement therapy: different methods to improve safety. Contrib Nephro 165:251–262CrossRef
10.
Zurück zum Zitat Antonic M, Gubensek J, Buturović-Ponikvar J, Ponikvar R (2009) Comparison of citrate anticoagulation during plasma exchange with different replacement solutions. Ther Apher Dial 13(4):322–326CrossRef Antonic M, Gubensek J, Buturović-Ponikvar J, Ponikvar R (2009) Comparison of citrate anticoagulation during plasma exchange with different replacement solutions. Ther Apher Dial 13(4):322–326CrossRef
11.
Zurück zum Zitat van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC (1996) Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 7:45–50 van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC (1996) Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 7:45–50
12.
Zurück zum Zitat Monchi M (2017) Citrate pathophysiology and metabolism. Transfus Apher Sci 56(1):28–30CrossRef Monchi M (2017) Citrate pathophysiology and metabolism. Transfus Apher Sci 56(1):28–30CrossRef
13.
Zurück zum Zitat Uhl L, Maillet S, King S, Kruskall MS (1997) Unexpected citrate toxicity and severe hypocalcemia during apheresis. Transfusion 37:1063–1065CrossRef Uhl L, Maillet S, King S, Kruskall MS (1997) Unexpected citrate toxicity and severe hypocalcemia during apheresis. Transfusion 37:1063–1065CrossRef
14.
Zurück zum Zitat Hester JP, McCullough J, Mishler JM, Szymanski IO (1983) Dosage regimens for citrate anticoagulants. J Clin Apher 1:149–157CrossRef Hester JP, McCullough J, Mishler JM, Szymanski IO (1983) Dosage regimens for citrate anticoagulants. J Clin Apher 1:149–157CrossRef
15.
Zurück zum Zitat Sigler K, Lee J, Srivaths P (2018) Regional citrate anticoagulation with calcium replacement in pediatric apheresis. J Clin Apher 33(3):274–277CrossRef Sigler K, Lee J, Srivaths P (2018) Regional citrate anticoagulation with calcium replacement in pediatric apheresis. J Clin Apher 33(3):274–277CrossRef
16.
Zurück zum Zitat Crookston KP, Novak DJ (2010) Physiology of apheresis. In: McLeod BC, Szczepiorkowski ZM, Weinstein R, Winters JL (eds) Apheresis: principles and practice. AABBPress, Bethesda, pp 45–69 Crookston KP, Novak DJ (2010) Physiology of apheresis. In: McLeod BC, Szczepiorkowski ZM, Weinstein R, Winters JL (eds) Apheresis: principles and practice. AABBPress, Bethesda, pp 45–69
17.
Zurück zum Zitat Marques MB, Huang ST (2001) Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange. J Clin Apher 16:120–124CrossRef Marques MB, Huang ST (2001) Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange. J Clin Apher 16:120–124CrossRef
18.
Zurück zum Zitat Wright S, Steinwandel U, Ferrari P (2011) Citrate anticoagulation using ACD solution A during long-term haemodialysis. Nephrology (Carlton) 16(4):396–402CrossRef Wright S, Steinwandel U, Ferrari P (2011) Citrate anticoagulation using ACD solution A during long-term haemodialysis. Nephrology (Carlton) 16(4):396–402CrossRef
19.
Zurück zum Zitat Weiss R, Fischer MB, Weber V (2017) The impact of citrate concentration on adhesion of platelets and leukocytes to adsorbents in whole blood lipoprotein apheresis. J Clin Apher 32(6):375–383CrossRef Weiss R, Fischer MB, Weber V (2017) The impact of citrate concentration on adhesion of platelets and leukocytes to adsorbents in whole blood lipoprotein apheresis. J Clin Apher 32(6):375–383CrossRef
20.
Zurück zum Zitat Puppe B, Kingdon EJ (2014) Membrane and centrifugal therapeutic plasma exchange: practical difficulties in anticoagulating the extracorporeal circuit. Clin Kidney J 7:201–205CrossRef Puppe B, Kingdon EJ (2014) Membrane and centrifugal therapeutic plasma exchange: practical difficulties in anticoagulating the extracorporeal circuit. Clin Kidney J 7:201–205CrossRef
21.
Zurück zum Zitat Brandenburger T, Dimski T, Slowinski T, Kindgen-Milles D (2017) Renal replacement therapy and anticoagulation. Best Pract Res Clin Anaesthesiol 31(3):387–401CrossRef Brandenburger T, Dimski T, Slowinski T, Kindgen-Milles D (2017) Renal replacement therapy and anticoagulation. Best Pract Res Clin Anaesthesiol 31(3):387–401CrossRef
22.
Zurück zum Zitat Rodnitzky RL, Goeken JA (1982) Complications of plasma exchange in neurological patients. Arch Neurol 39:350–354CrossRef Rodnitzky RL, Goeken JA (1982) Complications of plasma exchange in neurological patients. Arch Neurol 39:350–354CrossRef
Metadaten
Titel
Application of regional citrate anticoagulation in membrane therapeutic plasma exchange
verfasst von
Fang Yuan
Zheng Li
Xiejia Li
Hong Liu
Publikationsdatum
01.08.2020
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 12/2020
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-020-02581-0

Weitere Artikel der Ausgabe 12/2020

International Urology and Nephrology 12/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.